Shukra Pharmaceuticals Ltd
Shukra Pharmaceuticals: No Deviation in Preferential Issue Fund Utilization
RESULTS
● No Immediate Change
LOW RISK
📅 Filed on BSE: 07 May 2026, 10:38 PM IST · BSE ID: 0f4cce0c-4054-44a6-a7d3-e3e263bce8ce
View Original BSE Filing (PDF)
💡
In Simple Terms
The company confirmed that money raised from selling special shares is being used exactly as planned, with no changes.
🤖 AI Summary
- Shukra Pharmaceuticals reported no deviation in the utilization of funds from its preferential issue.
- The company raised ₹ 3,94,65,500, which is 25% of the total consideration for the preferential issue.
- Funds were raised on January 28, 2026, via issuance of convertible warrants for cash consideration.
- The primary objects for fund utilization include working capital, debt repayment, and capital expenditure.
- The Audit Committee reviewed the statement of deviation and provided no comments.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Amount Raised (25% of consideration)
₹ 3,94,65,500
Total amount raised under Rights issue
₹ 15,78,62,000
Working capital & capital allocation (in lakhs)
394.63
General Corporate Purposes allocation (in lakhs)
0.024
🏢 How This Affects the Company
The utilization of funds for working capital, repayment of borrowings, and capital expenditure supports ongoing business operations and potential expansion plans within the same line of business.
The receipt and deployment of ₹ 3,94,65,500 ensures that the company has access to capital for stated objectives, which can impact its liquidity and balance sheet structure.
Allocation towards working capital and capital expenditure directly supports operational needs and asset base growth, reinforcing existing business activities.
Confirmation of no deviation in fund utilization reduces the risk of regulatory non-compliance under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👥 What This Means For Shareholders
✅
Action Required
No specific action is required by shareholders based on this disclosure.
👤
Who Is Affected
Shareholders who participated in the preferential issue or those monitoring the company's financial discipline are primarily affected, as the funds raised are being utilized as per the approved objects.
🔍
Management Signal
The disclosure signals management's adherence to regulatory requirements and commitment to utilizing raised funds as per stated objectives.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly financial results — review capital deployment and financial health.
Annual report for FY26 — verify comprehensive fund utilization details.
Any further filings regarding the remaining 75% of preferential issue consideration.
LOW RISK
The filing explicitly states no deviation in fund utilization, reducing financial and regulatory risks associated with capital deployment.
💡 Investor Takeaway
Shukra Pharmaceuticals has confirmed no deviation in the utilization of ₹ 3,94,65,500 raised through convertible warrants on January 28, 2026. Funds are being used for working capital, debt repayment, capital expenditure, and general corporate purposes as originally planned.
⚖️ Strengths & Concerns
✅ Positives
- Confirmation of no deviation in fund utilization, aligning with the stated objects for the ₹ 3,94,65,500 raised.
- The Audit Committee has reviewed the fund utilization and provided no adverse comments, indicating internal oversight.
📅 Company Track Record
Shukra Pharmaceuticals previously reported audited financial results for Q4 FY26, disclosing a standalone net loss of Rs. (18.79) Lakhs and recommending a Rs. 0.01 dividend. A Board meeting was held on May 7, 2026, to approve these results and the final dividend. This current filing relates to the utilization of funds from a preferential issue initiated on January 28, 2026.
Based on publicly available historical data. For context only.